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Potential Indirect Anti-Inflammatory Effects of IL-4
Stimulation of Human Monocytes, Macrophages, and Endothelial Cells by IL-4 
Increases Aminopeptidase-N Activity (CD13; EC 3.4.11.2)1
Peter Th. W. van Hal,*+2 Johanna P. M. Hopstaken-Broos,* Arie Prins,*
Emmanuel J. Favaloro,* Richard J. F. Huijbens,§ Chris H ilvering/ Carl G. Figdor,§ and 
Henk C. Hoogsteden+
*Departments of Immunology and fPulmonary Medicine, Erasmus University and University Hospital Dijkzigt, Rotterdam, 
the §Division of Immunology, The Netherlands Cancer institute, Antoni van Leeuwenhoek Huis, Amsterdam, The 
Netherlands, and the ^Department of Haematology, Westmead Hospital, Westmead, Australia
IL-4 up-regulates various monocytic properties that are associated with pro-inflammatory functions. Paradoxically, 
IL-4 may also act as an anti-inflammatory agent by down-regulating the production of several inflammatory 
mediators. As the activity of some mediators has recently been shown to be regulated by peptidases, we examined 
whether IL-4 was able to modulate the expression of a cell membrane-associated peptidase, aminopeptidase-N 
(CD13). IL-4 caused a dose-dependent increase in the expression of CD13 Ag on highly purified human blood 
monocytes. Maximal expression was observed around 48 h of culture. This IL-4-induced increase was completely 
blocked by anti-IL-4 antiserum. Furthermore, the increase in surface expression was preceded by increased mRNA 
levels of CD13, which was maximal around 24 h of culture. We also observed that CD13-mediated leucine- 
aminopeptidase activity of monocytes was induced by IL-4. Other CD13-expressing cells were also sensitive to 
IL-4, as CD13 Ag expression and CD13 mRNA levels were up-regulated in human alveolar macrophages and 
endothelial cells upon IL-4 treatment. The increased expression of cell membrane aminopeptidase-N represents a 
potentially increased cellular ability to inactivate inflammatory mediators. Therefore, these findings represent 
further evidence of IL-4-mediated anti-inflammatory actions. We postulate that up~regulation of aminopeptidase-N 
expression may be an indirect mechanism of IL-4 to modulate the action of bioactive peptides. This mechanism 
may underlie, at least partially, the anti-inflammatory effects of IL-4 in vivo. The Journal of Immunology, 1994, 
153:2718.
I L-4 was originally characterized by its ability to ef­fect differentiation of resting B lymphocytes (1). More recently, it has been shown that IL-4 may also 
display a wide range of effects on several cell types (2). It 
can act as a growth factor for activated T lymphocytes, 
thymocytes, NK cells (3-5), and mast cells (5, 6). In ad­
dition, monocytic cells can also be influenced by IL-4,
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which is reported to induce monocyte maturation3 (7). 
Furthermore, some of the actions of IL-4 on monocytic 
cells are considered to be stimulatory. IL-4 increases ex­
pression of MHC class II Ag (7), increases antigen-pre­
senting capacity (8), and induces FceRIIb expression (9). 
IL-4 appears also to inhibit some parameters of monocyte 
activation. Thus, IL-4 inhibits super oxide production (10), 
inhibits the release of PGE2 (11), IL-1/3 (11-14), IL-6 (12, 
15, 16), IL-8 (17), TNF-a (11-13), and up-regulates the 
production of IL-1R antagonist (14, 18). Based upon the 
latter findings, it was suggested that IL-4 may have anti­
inflammatory properties (11-19).
During our studies on the influence of cytokines on 
monocytes and macrophages, we observed that IL-4 was
3 Van Hal, P.Th.W., H.C. Hoogsteden, A.A. te Velde, J.M, Wijkhuijs, C.C. 
Figdor, and C. Hilvering. IL-4-induced maturation of monocytes/macrophages 
is inhibited by glucocorticoids. Submitted for publication.
0022-1767/94/$02.00
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also able to modulate the expression of aminopeptidase-N. 
Initially, this enzyme (EC 3.4.11.2, gplSO, CD 13) was 
designated as a marker for subpopulations of hemopoietic 
cells (20-23). Currently, it is generally accepted that many 
other cell types (including fibroblasts, the renal tubular and 
intestinal epithelium (24, 25), endothelial cells (EC)4(26, 
27), and synaptic membranes of cells of the central ner­
vous system (28)) express this enzyme. It is hypothesized 
that aminopeptidase-N also plays an important role in 
modulating the activity of bioactive oligopeptides, com­
parable to the role of neutral endopeptidase (EC 3.4.24.11) 
(29-32). Accordingly, aminopeptidase-N may play a role 
in regulation of inflammatory and immunologic responses. 
Modulation of the expression of aminopeptidase-N may 
therefore influence these oligopeptide-mediated responses. 
In this report, we demonstrate that IL-4 is able to up-reg- 
ulate the expression of CD13 Ag on monocytic cells. 
Up-regulation is also seen in non-monocytic cells (in casu, 
endothelial cells), although this was less pronounced. This 
up-regulation is accompanied by an increase in aminopep- 
tidase-activity, indicating that cells activated by IL-4 may 
acquire potential anti-inflammatory properties.
Materials and Methods
Isolation of PBM
Human PBM were isolated from 500 ml blood from healthy volunteers 
as described elsewhere (33). Briefly, mononuclear cells were separated 
by density centrifugation with a blood component separator. Next, the 
mononuclear cells were fractionated into lymphocytes and monocytes by 
centrifugal elutriation. The monocyte preparation was over 95% pure as 
judged by May-Griinwald Giemsa staining and contained more than 98% 
viable cells as judged by trypan blue exclusion. Lymphocytes and gran­
ulocytes constituted less than 2% and 3% of the monocyte preparation, 
respectively. Before analysis of the surface membrane determinants the 
cells were washed twice with a PBS solution (300 mM; pH 7.8) supple­
mented with 0.5% heat-inactivated BSA (Organon Teknika, Oss, The 
Netherlands). Before isolation of total RNA or detection of LAP activity 
the cells were washed twice with a PBS solution.
Isolation of AM
All lavage studies were approved by the Medical Ethics Committee of the 
Erasmus University/University Hospital Dijkzigt, Rotterdam. BAL was 
performed in healthy, nonsmoking volunteers after premedication with 
thiazinamium and local anesthesia using a Iidocaine (2%, w/v) spray. The 
bronchoscope was placed in wedge position in the right middle lobe, and 
four aliquots of 50 ml sterile saline solution were infused and aspirated 
immediately in a siliconized specimen trap placed on melting ice. Im­
mediately after collection, the BAL fluid was strained through a sterile 
nylon gauze to trap large mucus particles, after which the BAL cells were 
isolated by centrifugation at 4°C at a force of 400 X g.  More than 90% 
of the BAL cells appeared to be macrophages, as judged by May-Griin- 
wald Giemsa staining. Before analysis of the surface membrane deter­
minants the cells were washed twice with PBS/0.5% BSA. Before iso­
lation of total RNA or detection of LAP activity the cells were washed 
twice with a PBS solution.
4 Abbreviations used in this paper: EC, endothelial cells; PBM, peripheral
blood monocytes; AM, alveolar macrophages; LAP, L-Ieucine-aminopepti-
dase-N; BAL, bronchoalveolar lavage; GAM, goat anti-mouse Ig antiserum;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Isolation o f EC
Human EC were isolated from umbilical cord vein by collagenase di­
gestion as described elsewhere (34).
Cell lines
THP-l cells (35) were used as control cells because of their CD 13 mRNA 
and CD 13 Ag expression. They were obtained from the American Type 
Culture Collection (Rockville, MD) and maintained according to their 
instructions.
rlL-4, rlL-2, rIFN-y, GM-CSF, LPS, and anti-IL-4 
antiserum
Human rIL-4 was a generous gift of Dr. H.F.J. Savelkoul of our depart- 
ment and Dr. K, Arai (DNAX Research Institute, Palo Alto, CA). Human 
rIL-2 was obtained from Eurocetus (Amsterdam, The Netherlands). 
Human rIFN-7 (specific activity 107 U/mg) and human rGM-CSF (spe­
cific activity 107 U/mg) were kindly provided by Drs. P. Trotta and
S. Naghabhushan (Schering-Plough Corp, Bloomfield, NJ). LPS (E. coli 
0127:B8) was purchased from Difco Laboratories (Detroit, MI). A poly­
clonal rabbit anti-IL-4 antiserum was used to block the biologic activity 
of IL-4, as has been described elsewhere (36).
Culture of cells
PBM and AM were cultured in a modified Iscove’s medium (Life Tech­
nologies, Inc., Paisley, U.K.) as described elsewhere (37), in which BSA 
was replaced by human serum albumin. In some experiments this me­
dium was supplemented with 2% autologous heat-inactivated serum. The 
culture medium was found to be endotoxin free (defined as less than 1.0 
ng endotoxin/ml as quantified by the Limulus amebocyte lysate assay). 
PBM (2-4 X lO^/ml) and AM (1-2 X 106/ml) were cultured at 37°C, 5% 
C 02, and 100% humidity in Teflon bags (Janssen’s MNL, St-Niklaas, 
Belgium) for 1 to 7 days. For detection of surface membrane determi­
nants, isolation of total RNA, or detection of LAP activity, cells were 
harvested from the Teflon bags and separated from the culture superna­
tant by centrifugation. Subsequently, the cells were washed twice with 
either PBS/0.5 % BSA/0,5% sodium azide when cells were used for de­
tection of surface membrane determinants, or PBS when cells were used 
for isolation of total RNA or detection of LAP activity. The viability as 
determined by propidium iodide or trypan blue exclusion exceeded 85%. 
The numbers of cells recovered after culture in the presence of rIL-4, 
rIL-2, or anti-IL-4 antiserum did not differ significantly.
EC were cultured in flat-bottom 6-well plates as described elsewhere 
(38). For detection of CD 13 Ag expression, plates were washed twice 
with PBS (37°C) to remove nonviable, nonadherent EC. Thereafter, EC 
were incubated (5 min* 37°C) with a collagenase solution (Worthington, 
Biochemical Corporation, NJ) to harvest adherent cells, From this point, 
EC were handled as PBM and AM. For isolation of total RNA, plates 
were washed twice with PBS (37°C). Thereafter, adherent cells were 
homogenized with 0.5 ml of solution D and transferred to 1.5-ml Ep- 
pendorf tubes. From this point, EC were handled as PBM and AM.
Detection o f surface membrane determinants
For immunofluorescence stainings of PBM, AM, and EC the following 
mAb were used: CD13 (Q20(IgG2a), Dr. C. E. van der Schoot, CLB, 
Amsterdam, The Netherlands; My7 (IgGl), Coulter Clone, Hialeah, FL); 
CD23 (Tul(IgGl), Biotest, Dreieich, Germany; Leu-20 (IgGl), Beet on 
Dickinson, San Jose, CA). Isotype-matched control Abs were directed 
against idiotypic determinants on a B cell lymphoma cell line and did not 
react with monocytes, macrophages, or endothelium. Fifty microliters of 
the EC, PBM, or AM cell suspension (2 X 106 cells/ml) were incubated 
for 30 min at 4°C with 50 ¡A of one of the (optimally titrated) mAbs. 
Incubation was performed in U-bottom 96-well microtiter plates. After 
three washings the cells were incubated with FITC-labeled GAM F(ab ')2 
(De Beer Medicals B.V., Hilvarenbeek, The Netherlands) for 30 min at 
4°C. After another three washings the cell pellets were resuspended for 
analysis of the fluorescence intensity by means of a FACScan (Becton 
Dickinson). The fluorescence intensities of Ag expression are expressed 
as a ratio relative to the background fluorescence intensity of cells stained
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FIGURE 1. Kinetics of the effect of IL-4 
on the cell membrane expression of CD13 
Ag on human PBM. Monocytes were cul­
tured without (O) or with ( • )  100 U IL-4/ 
ml. On the ordinate is given the relative 
fluorescence, i.e., the ratio between the 
mean linear fluorescence intensity of cells 
labeled with CD13 mAb and the mean lin­
ear fluorescence intensity of cells labeled 
with an IgG2a control Ab. Data of a rep­
resentative experiment out of five is 
shown.
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with an isotype-matched control Ab, A value of 1.0 reflects fluorescence 
equivalent to background. When fluorescence intensity was determined 
on cultured cells, background fluorescence was determined on similarly 
cultured cells.
All standard washings were performed with PBS/0.5% BS A/0.5 % so­
dium azide.
Preparation of total cellular RNA and Northern blot 
analysis
Total cellular RNA was isolated from THP-1 cells, freshly isolated or 
cultured PBM and AM, and cultured BC largely according to Chomc- 
zynski and Sacchi (39). Briefly, cells (5-10 X 106) were homogenized 
with 0.5 ml of solution D in a 1.5-ml Eppendorf tube. Sequentially, 50 ¿d 
of 2 M sodium acetate (pH 4,0), 0.5 ml of water-saturated phenol, and 0.1 
ml of chloroform were added to the homogenate, with thorough mixing 
after the addition of each reagent. The final suspension was cooled on ice 
for 15 min, Samples were centrifuged at 10,000 X g for 15 min at 4DC, 
The aqueous phase was transferred to a fresh tube containing 0.6 ml of 
isopropanol, and then placed at 4°C for at least 6 h to precipitate RNA. 
RNA was recovered by centrifugation (10,000 X g, 15 min, 4°C), dis­
solved in 0,3 to 0.5 ml solution D, and precipitated again with 1 volume 
of isopropanol. After centrifugation (10,000 X g, 15 min, 4°C), the RNA 
pellet was washed in 0.6 to 1.0 ml 75% ethanol and eventually dissolved 
in 25 to 50 jul RNase-free water. Total RNA (5-20 fig) was separated by 
electrophoresis in a 1% agarose gel (40)» subsequently vacuum trans­
ferred (41) onto a nylon membrane (NY-13 N; Schleicher & Schuell, 
Dassel, Germany), fixed to the membrane with a 254 nm UV crosslinker 
(Stratalinker, Stratagene, La Jolla, CA), and hybridized with a CD 13 
probe, which was labeled according to the Klenow oligonucleotide 
method (42). The CD 13 cDNA probe was prepared as described else­
where (43). Prehybridization and hybridization of RNA blots were per­
formed as described elsewhere (40). After hybridization the blots were 
washed and exposed to Fuji NIF-RX films (Fuji Photo Film Co., Tokyo, 
Japan) with intensifying screens. The quality and the amounts of RNA 
applied were controlled by rehybridization of the blots with a GAPDH 
probe. This probe was a 0,7-kb EcoRI - Pstl fragment (44).
Semiquantification of CD13 mRNA levels
The relative density for bands on autoradiograms was estimated by laser 
scanning densitometry (video densitometer model 620, Bio-Rad Labo­
ratories, Richmond, CA). Each gel containing RNA from kinetic IL-4 
experiments with PBM, AM, or EC also contained a series of seven 1:2 
dilutions (0.5-32 jag) of total RNA isolated from CD 13 mRNA+ THP-1 
cells. As the linear relationship between band density on autoradiograms 
and the quantity of CD13 mRNA is only limited, we related the density 
of a particular CD 13 band from PBM, AM, or EC to bands of comparable 
density in the dilution series of CD 13 bands from THP-1 cells. In this 
way, it was possible to quantitate, indirectly but in a linear way, CD13
bands of different density from PBM, AM, or EC, whether or not they 
were exposed to IL-4 during different periods of time. CD 13 mRNA 
levels are expressed in units, where a value of X represents the level of 
CD 13 mRNA (present in the quantity of electrophorized total RNA) that 
is identical to the level of CD13 mRNA in X fig of THP-1 total RNA. If 
X is greater than the quantity of electrophorized total RNA, the particular 
cell sample contained relatively more CD13 mRNA than THP-1 cells. 
The same procedure was applied to estimation of GAPDH band densities.
For final interpretation of CD13 mRNA levels, i.e., to compensate for 
differences in RNA loading per lane or culture-induced influences on 
general mRNA levels, CD 13 mRNA levels were related to GAPDH 
mRNA levels.
Functional assay for LAP-activity
The presence of aminopeptidase-N activity on PBM was detected largely 
as described elsewhere (45). Briefly, the assay was performed in triplicate 
in flat-bottom wells of 96-well microtiter plates. Fifty microliters of a cell 
suspension (0.5 - 1.0 X 106 cells/ml) were incubated with 50 /xl of l- 
leucine-p-nitroanilide (Sigma Chemical Co.) (8.36 mM) for 30 min at 
37°C. After this incubation enzymatic activity was blocked by addition of 
35 /xl of a 30% (v/v) acetic acid solution. The increase in specific ab­
sorbance at 405 nm (as a result of accumulation of free /;-nitroanilide) 
was determined by using a Titertek Multiskan MCC plate reader (I.C.N. 
Biomedicals B.V., Amsterdam, The Netherlands). Aminopeptidase-N ac­
tivity was expressed as the production of p-nitroanilide in 30 min by 10fi 
cells (nmol/3'0 min X 106 cells).
In some experiments cells were pre-incubated with the CD 13 mAb 
WM15 (IgGl, Dr. E. J. Favaloro, Westmead, Australia) for 30 min at 4°C 
to block CD13-mediated LAP-activity. As a control procedure, cells were 
pre-incubated with an isotype-matched control Ab. After this pre-incu­
bation, cells were directly assayed for their LAP-activity as described 
above.
Results
IL-4 up-regulates CD13 Ag expression on human 
monocytes
Freshly isolated PBM expressed CD 13 Ag. However, even 
after one day of culture, expression of CD13 Ag was found 
to increase significantly upon IL-4 treatment (Fig. 1, 
closed circles). This increase was seen consistently in all 
experiments (n =  9). Maximal increase was observed 
around day 2 of culture. To a limited extent, CD13 Ag 
expression was also enhanced in control cultures of PBM 
(Fig. 1, open circles). These findings could not be ex­
plained by an increase in cell size, as there was only a
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Table I. Influence o f IL-4 on the expression o f the CD13 Ag on 
blood monocytes can be blocked by anti-IL-4 anti serum a
Medium +
Medium +- IL-4 (100 U/ml) +
Days of Culture Medium IL-4 (100 U/ml) Anti-IL-4
0 17.3b 17.3 17.3
3 35.2 94.8 34.3
* Freshly isolated monocytes or monocytes cultured either in control me­
dium or in the presence of IL-4 alone or both IL-4 and anti-IL-4 were labeled 
with Q20(CD13) and FITC-conjugated GAM F(ab')2. A representative experi­
ment out of seven is shown.
b Data are expressed as relative fluorescence, i.e., the ratio between the 
mean linear fluorescence intensity of cells labeled with the relevant Ab and 
the mean fluorescence intensity of cells labeled with the iso type-matched 
control Ab.
limited rise in forward light scatter signal after 2 days, and 
CD13 Ag expression decreased upon further culture al­
though cell size increased gradually. After more than 2 
days of culture, expression of CD13 Ag diminished, but 
even after 7 days of culture expression was higher than the 
expression on freshly isolated PBM or PBM cultured in 
medium without IL-4. This IL-4-induced increase was de­
pendent on the concentration of IL-4 and could be blocked 
by anti-IL-4 antiserum (Table I). We also studied whether 
other cytokines were able to affect CD 13 Ag expression 
comparably to IL-4. Therefore, we cultured PBM for 2 or 
3 days with either IL-2, IFN-y, GM-CSF or LPS. Neither 
LPS nor these cytokines were able to induce any addi­
tional increase in CD13 Ag expression as compared with 
the spontaneous increase observed when cells were cul­
tured in control medium (Table II). Taken together, these 
results suggest that the transient increase in CD 13 Ag ex­
pression upon culture with IL-4 is specific for IL-4.
IL-4 increases CD13 mRNA levels in human 
monocytes
To investigate whether increased CD13 Ag expression re­
quired enhanced mRNA levels, total RNA was prepared 
from freshly isolated PBM, and PBM after culture without 
or with IL-4. Total RNA was size-separated by electro­
phoresis and hybridized with the 32P-labeled CD13 cDNA 
probe and, at a later point of time, the 32P-labeled GAPDH 
cDNA probe. Analysis of the CD13 mRNA levels showed 
that culture of PBM with IL-4 caused a consistent and 
marked additional increase in CD13 mRNA level, as com­
pared with the spontaneous increase in control cultures 
(Fig. 2). Maximal induction of CD13 mRNA was seen 
around day 1 of culture. Semiquantification of the mRNA 
levels revealed that the level of CD 13 mRNA after 1 day 
of culture in medium without IL-4 was more than 10 times 
as high as the level in freshly isolated PBM. After 1 day of 
culture in medium with IL-4, the level of CD 13 mRNA 
was more than 30 times as high (Table III). Culture of 
PBM for a longer period of time revealed that the level of 
CD 13 mRNA gradually diminished after day 1 of culture. 
Without IL-4, the level of CD 13 mRNA decreased to the
level of freshly isolated PBM after 5 days of culture. With 
IL-4, the level of CD 13 mRNA also decreased, but was still 
markedly increased even after 5 days of culture (Fig. 2 and 
Table I). These results indicate that IL-4 specifically in­
creased the level of CD13 mRNA, and that maximal induc­
tion of CD13 mRNA preceded maximal IL-4-induced ex­
pression of CD13 Ag on the cell surface by one day,
Influence of IL-4 on LAP activity of cultured human 
monocytes
To determine whether the IL-4-induced up-regulation of 
CD 13 mRNA levels and CD 13 Ag expression in PBM was 
accompanied by a functional increase in aminopeptidase 
activity, we studied whether PBM cultured with IL-4 
would degrade a chromogenic substrate more efficiently 
than PBM cultured without IL-4, Initially, freshly isolated 
and shortly cultured PBM were assayed for their capacity 
to degrade L -le u c in e -/7 -n itro a n ilid e . These experiments re­
v e a le d  a decrease in LAP activity after 1 or 2 days of 
culture whether IL-4 was present or not, although in all 
experiments LAP activity was significantly higher in the 
IL-4-treated PBM than in the nontreated PBM (data not 
shown). As other membrane enzymes may also display 
LAP-like activity comparable to CD 13 Ag (Dr. E. 
Favaloro, unpublished data), we tried to make our assay 
more specific for LAP activity resulting from CD 13 Ag. 
Therefore, we pre-incubated cultured PBM with the mAb 
WM-15, which has been described as blocking LAP ac­
tivity resulting from CD13 Ag (23) or, as a control pro­
cedure; with an isotype-matched control Ab. Furthermore, 
we studied the kinetics of the effect of IL-4 on LAP ac­
tivity in more detail. After culturing PBM without IL-4, 
we observed an unchanged or slightly decreased total (i.e., 
after pre-incubation with a control Ab) LAP activity de­
spite the invariably observed increases in CD13 mRNA 
level and CD13 Ag expression (Fig. 3, open circles of 
panels A  and C). After 1 day of culture with IL-4, PBM 
showed only a slight increase or a slight decrease in total 
LAP activity (Fig. 3, closed circles of panels A  and C). 
Upon further culture, however, a gradual increase in total 
LAP activity was seen. Maximal total LAP activity was 
seen around 60 h of culture with IL-4. Culture with IL-4 
for more than 60 h resulted in a decrease of total LAP 
activity. During the whole culture period, total LAP ac­
tivity of PBM cultured with IL-4 was higher than total 
LAP activity of PBM cultured without IL-4. This was ob­
served in all our experiments (n =  4).
CD13-specific LAP activity of PBM cultured without 
IL-4 (i.e., the decrease of LAP activity after pre-incubation 
with the mAb WM-15) also decreased upon culture (Fig.
3, open circles of panels B and D ), whereas this enzyme 
activity of PBM cultured with IL-4 showed a transient 
increase that was maximal around 60 h of culture (Fig. 3, 
closed circles of panels B and D). The apparent discrep­
ancy between the increased CD13 Ag expression already
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Table II. Influence o f IL-2, IFN-y, GM-CSF, and LPS on the expression o f the CD13 Ag on blood monocytes as compared with the 
influence o f IL-4
Days of Culture Medium Medium -1- IL-2 Medium + IFN-y Medium + GM-CSF Medium + LPS Medium + IL-4
0 39.3b 39.3 39.3 39.3 39.3 39.3
3 59.1 61.6 24.9 48.9 55.4 143.6
a Freshly isolated monocytes or monocytes cultured either in control medium or in the presence of one of the indicated cytokines (IL-2, IFN-y, GM-CSF, IL-4) 
or LPS were labeled with Q20 (CD13) and FITC-conjugated GAM F(ab')2. A representative experiment out of three is shown. 
b Data are expressed as relative fluorescence, calculated as described in the footnote to Table I.
Kinetics of the expression of CD13 mRNA
in cultured blood monocytes
o 1 2
I----------1 I------
+
day
IL-4
A Kb
- 28S
4.0 -
- 18S
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tivity of PBM in our experiments, we concluded that in our 
experiments other enzymes also displayed LAP-like activ­
ity. How expression and function of these other enzymes 
are influenced by IL-4 is unclear.
Influence of IL-4 on the expression of CD13 Ag and 
CD13 mRNA levels in cultured human AM
We have demonstrated earlier that freshly isolated AM 
express CD 13 Ag (43). Upon culture, a spontaneous and 
transient increase in CD 13 Ag expression was observed, 
comparable with PBM. Likewise, IL-4 induced a more 
substantial increase in CD 13 Ag expression with a maxi­
mum around day 2 of culture (Fig. 4, right panel). We 
studied also the kinetics of the effect of IL-4 on CD 13 
mRNA levels in AM. As in PBM, we observed an IL-4- 
induced rise in the level of CD 13 mRNA. This increase 
was significantly larger than the spontaneous increase that 
was seen upon culture without IL-4 (Fig. 5, lanes 2 and 3). 
Furthermore, this increase was already seen after 5 h of 
culture and was maximal after 1 day of culture. The level 
of CD 13 mRNA decreased upon further culture. After 4 
days of culture, the level of CD 13 mRNA in AM cultured 
with IL-4 did not differ any more from the level in AM 
cultured without IL-4 (Fig. 5, lanes 8 and 9).
1.2 -
Influence of IL-4 on the expression o f CD 13 Ag and 
CD13 mRNA levels in cultured human EC
In our experiments we could confirm, as has been dem­
onstrated elsewhere (26, 27), that human endothelial cells 
in in vitro culture expressed CD13 Ag. After only 13 h of 
culture in the presence of IL-4 (100 U/ml), we found al­
ready a slight increase in the expression of CD 13 Ag (rel­
ative fluorescence increased from 100 ±  11% to 122 ±  
7% (n =  2)). Maximal increase of CD13 Ag expression 
was observed between 24 and 48 h of culture. The left- 
hand panel of Figure 4 shows the maximal IL-4-induced 
expression of CD13 Ag of one representative experiment 
(relative fluorescence increased from 7.9 (100%) to 18.8 
(238%)). Incubation for more than 48 h resulted in a de- 
seen after 1 day of culture with IL-4 and the initially un- crease of the expression of CD13 Ag. Therefore, the tran- 
changed LAP activity was also observed. Because mAb sient induction of CD13 Ag expression in human EC re- 
WM-15 has been reported to block CD13-mediated LAP sembled the kinetics observed in our experiments with 
activity completely, but was unable to block all LAP ac- PBM and AM. Moreover, IL-4 also increased CD 13
FIGURE 2. Kinetics of the IL-4-induced up-regulation of 
CD13 mRNA expression in human PBM. Total RNA was pre­
pared from freshly Isolated monocytes ( lane 1), and from 
cells cultured in the absence (lanes 2, 4 and 6) or presence 
(lanes 3r 5 and 7) of 100 U IL-4/ml. Each lane contains 5 ¡xg 
of total RNA. RNA was size-separated by electrophoresis, 
transferred onto a nylon membrane, hybridized with the 32P- 
labeled CD13 cDNA probe, and exposed for 72 h (upper 
panel, A). The lower panel (B) shows the same membrane 
rehybridized with the GAPDH cDNA probe, which was used 
as the internal standard for RNA content,
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Table III. Time course o f the influence o f IL-4 on the level o f CD13 mRNA in human PBM a
Days of Culture
Medium Medium + IL-4
CD13 mRNA level GAPDH mRNA level
CD13 mRNA 
relative to 
GAPDH mRNA CD13 mRNA level GAPDH mRNA level
CD13 mRNA 
relative to 
GAPDH mRNA
0 < 2 b 5 .2 C <0.4^ <2 5.2 < 0.4
1 34,2 6.8 5,0 > 70 4.4 > 15.9
2 7.2 3.1 2.3 37.6 4.1 9.2
5 <2 4.7 < 0 .4 34.5 2.5 13.8
0 Total RNA was prepared from freshly isolated PBM and PBM cultured in medium either without or with 100 U IL-4/ml. After fractionation of 5 ju,g RNA in 
an agarose gel, transfer to a nylon membrane, hybridization with the CD13 or GAPDH cDNA probe, and exposure to a film, the relative radioactivity for bands 
on the autoradiogram was estimated by laser scanning densitometry. Results in this table are derived from the autoradiograms shown in Figure 2. A representative 
experiment out of three is shown.
b Data represent expression of CD13 mRNA in PBM relative to the expression in THP-1 cells. A vaiue of X represents the level of CD13 mRNA present in the 
quantity of total RNA used for electrophoresis (in casu, 5 \lg), which is identical to the level of CD13 mRNA present in X ¿¿g of total RNA isolated from THP-1 cells 
(see Materials and Methods for further explanation).
c Data represent expression of GAPDH mRNA in PBM relative to the expression in THP-1 cells. Interpretation of the data ¡s identical to the interpretation as 
described in footnote b.
rfData represent the ratio between the CD13 mRNA (footnote b) and GAPDH mRNA (footnote c) levels.
400
experiment 1
§ § 1 0 0
80 100 0 20 
hours of culture
FIGURE 3. Kinetics of the influence of IL-4 on the LAP activity of human PBM. Monocytes were assayed for their LAP activity 
directly after isolation (0 h of culture) and after culture without (O) or with ( • )  100 U IL-4/ml. Total LAP activity (panels A and 
C) represents enzyme activity of PBM that were pre-incubated with an lgG1 control Ab. CD13-specific LAP activity (panels B 
and D) is calculated by subtracting the remaining LAP activity of PBM that were pre-incubated with the mAb WM-15 from the 
total LAP activity, and assumes that after pre-incubation with WM-15 the only aminopeptidase activity detected is that which 
is not mediated by CD13 Ag.
mRNA levels in EC comparable with the increase seen in 
PBM and AM (Fig. 6).
Discussion
Although IL-4 was initially described as a B cell stimula­
tory factor, it is now also known to have regulatory activ­
ity on human monocyte and macrophage functions. IL-4 
may activate PBM to express FceRIIb and MHC class II
Ag (7-9), and may thus contribute to inflammatory pro­
cesses. Paradoxically, IL-4 has also been reported recently 
to display anti-inflammatory functions. The monocyte pro­
duction of several cytokines and reactive oxygen species is 
suppressed by IL-4 (10-18), and the capacity to lyse tu­
mor cells and microorganisms is decreased (10, 46, 47). 
Furthermore, IL-4 may control the accumulation of mono­
cytes in areas of inflammation by enhancing apoptosis in
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104 10°
FIGURE 4. Influence of IL-4 on the expression of CD13 Ag on human EC and AM. The left-hand panel represents EC that 
were stained with CD13 mAb and FITC-labeled GAM F(ab,)2/ either after a culture period of 2 days in medium without (C) or 
with (D; bold histogram) 100 U IL-4/ml. Histogram A represents EC stained with an lgG2a control Ab and FITC-labeJed GAM 
F(ab')2. One representative experiment out of two is shown. The right-hand panel represents AM that were also stained after 
a culture period of 2 days in medium without (Q  or with (D; bold histogram) 100 U IL-4/ml. Histogram A represents AM stained 
with an lgG2a control Ab and FITC-labeled GAM F(ab')2, whereas histogram B represents staining of freshly isolated AM with 
CD13 mAb and FITC-labeled GAM F(ab,)2. One representative experiment out of seven is shown. In both the left-hand and 
right-hand panels, fluorescence intensity of 7500 cells was determined on a log scale with a FACScan.
stimulated monocytes (19). Evidence that IL-4 may ex­
hibit anti-inflammatory properties is accumulating and the 
first results of the use of IL-4 in vivo have been published 
recently (48, 49).
In the present study, it is shown that IL-4 up-regulates 
the expression of CD 13 Ag on monocytes and macro­
phages, and thus may be a newly described mechanism mod­
ulating inflammation. The transient induction of CD13 Ag by 
IL-4 resembles the earlier reported IL-4-induced up-regula­
tion of FceRIIb on PBM (9,50). Maximal induction was seen 
after 2 days of culture. Kinetics of the IL-4-induced up-reg­
ulation of CD13 mRNA revealed maximal levels after 1 day 
of culture, indicating that peak mRNA levels preceded peak 
CD13 Ag expression. The increased CD13 mRNA levels 
may result from either IL-4-increased transcription or mRNA 
stability. Future nuclear run-off transcription experiments and 
mRNA half-life experiments may clarify this point. Indirect 
evidence that most IL-4 effects occur at the transcriptional 
level comes from other studies that described influences of 
IL-4 on mRNA transcription of IL-IRa (51), IL-2 (52), IL-6, 
CD23, and type I and III procollagen.
Functionally, we observed an IL-4-induced increase in 
LAP activity more or less coinciding with the IL-4-in- 
duced expression of CD13 Ag. Although PBM cultured in 
control medium also exhibited a slight, spontaneous in­
crease in CD'13 Ag expression and CD13 mRNA level, 
this was not accompanied by an increase in LAP activity 
in our experiments. This may be a result of a negative 
influence on the optimal functional enzyme structure when 
cells are isolated from the in vivo environment and trans­
ferred to the artificial in vitro culture conditions. Never­
theless, IL-4-treated PBM exhibited a higher LAP activity 
than untreated PBM, indicating that IL-4 is able to in­
crease the capacity of PBM to degrade aminopeptidase 
substrates. Not all LAP activity appeared to be a result of 
the presence of CD13 Ag, as the mAb WM-15 was unable 
to block LAP activity totally . This was demonstrated ear­
lier (53) and may indicate that other cell membrane enzymes 
also display aminopeptidase-N-like activity. A  more specific 
assay for measuring peptidase activity resulting from amin- 
opeptidase-N-activity (which is not available yet) would ad­
dress this issue appropriately.
PBM cultured in control medium exhibited a slight, 
spontaneous increase in CD13 mRNA and CD13 Ag. 
These increases in expression are unlikely to be caused by 
contaminating amounts of IL-4, as culture of PBM in the 
presence of both IL-4 and anti-IL-4 antiserum reduced 
CD 13 Ag expression to the levels of PBM cultured in 
control medium, and not to the levels of freshly isolated 
PBM. Furthermore, this spontaneous increase could not be 
explained by either serum components or LPS or cellular 
adherence, as culture of PBM under serum-free conditions 
gave similar results, culture in the presence of LPS did not 
result in a more pronounced increase, and PBM were cul­
tured under nonadherent conditions in Teflon bags.
Recently, it was described that activity of cell mem­
brane peptidases could be modulated by cellular envi­
ronmental factors. Werfel et al. demonstrated that the 
cell membrane expression of CD'13 Ag was rapidly in­
creased on PBM upon stimulation with C5a (54). This
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FIGURE 5. Kinetics of the IL-4-induced up-regulation of 
CD13 mRNA expression in human AM. Total RNA was pre­
pared from freshly isolated macrophages (lane 1), and from 
macrophages cultured either in the absence (fanes 2, 4, 6, 
and 5) or presence (lanes 3, 5, 7, and 9) of 100 U IL-4/ml. 
Each lane contains 5 ¡Mg of total RNA. RNA was electropho­
rized, transferred onto a nylon membrane, hybridized with 
the 32P-labeled CD13 cDNA probe, and exposed for 26 h 
{upper panel, A), The lower panel (B) shows the same blot 
rehybridized with the GAPDH cDNA probe, which was used 
as the internal standard for RNA content.
FIGURE 6. Kinetics of the JL-4-induced up-regulation of 
CD13 mRNA expression in human EC. Total RNA was pre­
pared from EC cultured either in the absence of IL-4 (lanes 1, 
3, 5, 7, and 9) or for 13 h, 25 h, 2, 3, and 4 days in the 
presence (lanes 2, 4, 6, 8, and 10) of 100 U lL-4/ml. Each 
lane contains 5 /xg of total RNA. RNA was electrophorized, 
transferred onto a nylon membrane, hybridized with the 32P- 
labeled CD13 cDNA probe, and exposed for 3 days (upper 
panel, A). The lower panel (B) shows the same blot rehybrid­
ized with the GAPDH cDNA probe, which was used as the 
internal standard for RNA content.
increase was observed within minutes, indicating trans­
location of an intracellular pool of CD 13 Ag to the cell 
surface. Together with our results presented here, this 
suggests that different mechanisms induce increased 
cell membrane expression of CD 13 Ag. Rohrbach and 
Conrad reported that LAP activity in cultured PBM was 
enhanced by the presence of T lymphocytes (55). A l­
though they did not speculate on the mechanism by 
which LAP activity was increased, we think that their 
results can be explained by the production of IL-4 by 
activated T lymphocytes, which is consistent with our 
own results. Kondepudi and Johnson studied another 
cell type and another cell membrane peptidase (56). 
They reported that several cytokines increased neutral 
endopeptidase activity in lung fibroblasts, and they sug­
gested that up-regulation of this peptidase may limit 
inflammation in the pulmonary interstitium. In their 
study, several cytokines were shown to increase neutral 
endopeptidase activity in human lung fibroblasts, but
our results show that IL-4 uniquely up-regulates CD 13 
A g expression and aminopeptidase-N-activity in human 
monocytes and macrophages. Our conclusion is sup­
ported by others who have shown that IFN-y and IL-10 
were without effect on CD 13 Ag expression in human 
monocytes (57).
Originally, the cell membrane glycoprotein (gp 150) de­
fined by CD 13 mAb has been regarded as a marker for 
subpopulations of hemopoietic cells (20-23). Nowadays, 
it is known to be expressed by a number of different cell 
types, including fibroblasts, the renal tubular and intestinal 
epithelium (24, 25), endothelial cells (26, 27), and synap­
tic membranes of cells of the central nervous system (28). 
Recently, the gene for this protein has been cloned, lead­
ing to the recognition of this protein as aminopeptidase-N 
(EC 3.4.11.2) (58). Aminopeptidase-N belongs to the group 
of ectoenzymes, so called because of their extracellularly lo­
cated catalytic sites (25, 29, 30). It has been speculated that 
the actual physiologic substrate(s) of these ectoenzymes may
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be either membrane bound, soluble, or part of the extracel­
lular matrix. Another member of this group, neutral endo­
peptidase (EC 3.4.24.11, common acute lymphoblastic leu­
kemia Ag, CD 10), has been studied extensively. This enzyme 
has been reported to process a number of biologically active 
peptides (59), including IL-1/3 (60), substance P (29, 61), 
enkephalin (62), C5a (63), and FMLP (64). Less is known 
about the physiologic substrate(s) of aminopeptidase-N, but 
substrates comparable to those of neutral endopeptidase have 
been suggested (31). This is strengthened by the findings that 
different peptidases may be able to process the same peptide, 
or that inactivation of biologically active peptides may re­
quire sequential hydrolysis by a battery of distinct ectoen- 
zymes in a multistep fashion (29, 30). In the central nervous 
system the role of aminopeptidase-N, together with other cell 
surface peptidases, is believed to be to inactivate neuropep­
tides (28). Comparatively, the action of neuropeptides at 
places of neurogenic inflammation (e.g., neurogenic inflam­
mation in asthmatic lungs) is thought to be terminated, at 
least partially, by enzymatic degradation (65, 66). It has been 
reported that neutral endopeptidase is able to inactivate the 
neuropeptide substance P, which plays an important role in 
the pathogenesis of asthma (61). As hydrolysis of a particular 
peptide may result from the single action of different pepti­
dases, and inactivation of biologically active peptides may 
need sequential hydrolysis by both endo- and exopeptidases 
(29, 30), aminopeptidase-N may, in concert with neutral en­
dopeptidase, play a role in modulating inflammation in in­
flammatory diseases such as asthma.
As IL-4 has also been described in PBM as down-reg- 
ulating cell membrane proteins such as CD 14 Ag3 and the 
three Fey R (47), and the physiologic substrate of ectoen- 
zymes may be membrane bound, IL-4-induced up-regula­
tion of aminopeptidase-N may, in the same cell, play a 
decisive role in processing other cell membrane-bound 
Ag. Transfection experiments in CD14+ or Fey R* cells 
using cDNA coding for enzymatically active aminopepti­
dase-N may clarify this issue.
The role of monocytes and macrophages in initiating 
and amplifying immunologic and inflammatory responses 
has been described extensively (67, 68). Both cell types 
may generate a variety of pro-inflammatory mediators and 
cytokines (68). On the other hand, it has been reported that 
macrophages may also be able to down-regulate inflam­
mation (69). This down-regulation may be (partially) me­
diated by cell membrane peptidases. The IL-4-induced in­
crease in LAP activity, as described here, may be a new, 
additional anti-inflammatory mechanism of IL-4.
In a role partly comparable to the role of monocytes and 
macrophages, EC are nowadays recognized as cells that 
actively participate in a variety of physiologic processes, 
such as inflammation and hemostasis (27, 70). Inflamma­
tion is characterized by perturbation of EC integrity, lead­
ing to increased vascular permeability. Several inflamma­
tory peptides may be responsible for the increase in 
vascular permeability. A  balanced regulation of produc­
tion and degradation of these peptides determines the final 
development of localized edema. Recently, it was shown 
that neutral endopeptidase plays an important role in mod­
ulating the edema-forming effects of bradykinin (70). In 
view of the effects on aminopeptidase-N activity, IL-4 
may therefore suppress indirectly the inflammatory re­
sponse by increasing the capacity of EC to degrade pro- 
inflammatory peptides.
In conclusion, our results show that IL-4 is able to in­
crease the expression of CD13 Ag on monocytes, macro­
phages, and endothelial cells. We postulate that up-regu­
lation of CD13 Ag expression may be an indirect 
mechanism of IL-4 for modulating the action of bioactive 
peptides.
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